Status:
COMPLETED
A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients
Lead Sponsor:
Mylan Bertek Pharmaceuticals
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A study to determine the safety, efficacy and superiority of nebivolol to placebo for the treatment of elevated blood pressure in patients with mild to moderate hypertension.
Detailed Description
This study was a multi-center, multi-national, randomized, double-blind, parallel group, placebo-controlled study of nebivolol over a range of doses in patients with mild to moderate hypertension. The...
Eligibility Criteria
Inclusion
- An average sitting diastolic blood pressure of greater then or equal to 95 mmHg and less then or equal to 109 mmHg at baseline
Exclusion
- Recent myocardial infarction or stroke
- Secondary hypertension
- Contraindications to beta-blocker therapy or discontinuation of prior antihypertensive agents
- Pregnancy, nursing or women of childbearing age not using appropriate contraception
Key Trial Info
Start Date :
September 1 2001
Trial Type :
INTERVENTIONAL
End Date :
March 1 2003
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT00200473
Start Date
September 1 2001
End Date
March 1 2003
Last Update
September 20 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mylan Pharmaceuticals Inc.
Morgantown, West Virginia, United States, 26505